Journal of Hepatology
Volume 44, Issue 1 , Pages 1-3 , January 2006

Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: Is adefovir dipivoxil the answer?

  • Chloe L. Thio

      Affiliations

    • Corresponding Author Information1503 E Jefferson St., Baltimore, MD 21231, USA. Tel.: +1 410 955 0349; fax: +1 410 614 7564.

References 

  1. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492–497
  2. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799–805
  3. Homann C, Krogsgaard K, Pedersen C, Andersson P, Nielsen JO. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr. 1991;4:416–420
  4. Rustgi VK, Hoofnagle JH, Gerin JL, Gelmann EP, Reichert CM, Cooper JN, et al. Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med. 1984;101:795–797
  5. Ling R, Mutimer D, Ahmed N, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 1996;24:711–713
  6. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 1996;24:714–717
  7. Benhamou Y, Bochet M, Thibault V, Di M, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302–1306
  8. Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS. 2003;17:1649–1657
  9. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–117
  10. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–1722
  11. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther. 2005;10:625–633
  12. Thio CL, Seaberg EC, Skolasky RL, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet. 2002;360:1921–1926
  13. Benhamou Y, Thibault V, Vig P, Calvez V, Marcelin A-G, Fievet M-H, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44: 62–67.
  14. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet. 2001;358:718–723
  15. Chen CJ, Yang HI, Su J, Jen CL, Kuo E, You SL. Viral load is a strong predictor of liver cirrhosis risk in people chronically infected with hepatitis B virus regardless of hepatitis B e antigen status. J Hepatol. 2005;42:476
  16. Marcellin P, Chang TT, Lim S, Sievert W, Tong M, Arterburn S, et al. Long term efficacy and safety of adefovir dipivoxil 10 mg in HBeAg+ chornic hepatitis B patients:increasing serologic, virologic and biochemical response over time. Hepatology. 2004;40:1135
  17. Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 1997;11:597–606
  18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352:2673–2681
  19. Hadziyannis S, Tassopoulos N, Chang T, Heathcote J, Kitis G, Rizzetto M, et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg negative chronic hepatitis B: results after 5 years of therapy. 56th Annual Meeting of the American Association for the Study of Liver Diseases. 2005;14;Abstract LB
  20. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE, Isom H, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology. 2003;37:27–35
  21. Lacombe K, Gozlan J, Boelle PY, Serfaty L, Zoulim F, Valleron AJ, et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS. 2005;19:907–915
  22. Van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40:1421–1425
  23. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Genotypic changes in HBV DNA of HBV/HIV co-infected patients after long-term exposure to tenofovir. Antivir Ther. 2005;10:727–734

PII: S0168-8278(05)00682-3

doi: 10.1016/j.jhep.2005.10.012

Journal of Hepatology
Volume 44, Issue 1 , Pages 1-3 , January 2006

Article Tools